Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News BioDelivery Sciences International Inc. BDSI

BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its products include Belbuca and Symproic.


Recent & Breaking News (NDAQ:BDSI)

BioDelivery Sciences Cites Impressive Number of Physicians Granted Waiver to Increase Patient Limit for Opioid Dependence Treatment Following Recent HHS Rule

PR Newswire September 30, 2016

Mid-Afternoon Market Update: Dow Falls Over 200 Points; Catabasis Shares Spike Higher

Benzinga.com  September 29, 2016

Watch These 5 Huge Call Purchases In Wednesday Trade

Benzinga.com  September 28, 2016

BioDelivery Sciences to Present at the Ladenburg Thalmann 2016 Healthcare Conference

PR Newswire September 21, 2016

White House To Loosen Controls On Heroin Addiction Treatment

Benzinga.com  July 6, 2016

BioDelivery Sciences to Present at the William Blair Annual Growth Stock Conference

PR Newswire June 8, 2016

BioDelivery Sciences Announces Presentation of Data on the Impact of a State Formulary Conversion to BUNAVAIL® at the International Conference on Opioids

PR Newswire June 6, 2016

New Data Demonstrate Safety Of Long-Term, Around-The-Clock Treatment With BELBUCA™ (Buprenorphine) Buccal Film For Chronic Pain

PR Newswire Europe Non Regulatory June 3, 2016

What Investors Think of These Biotech Stocks? - Genocea Biosciences, BioDelivery Sciences Intl., INSYS Therapeutics, and Agios Pharma

PR Newswire June 2, 2016

BioDelivery Sciences to Present at the Jefferies 2016 Healthcare Conference

PR Newswire June 2, 2016

BioDelivery Sciences and Collegium Pharmaceutical Announce the Signing of a Licensing Agreement for ONSOLIS® in the U.S.

PR Newswire May 11, 2016

Collegium Licenses the U.S. rights to ONSOLIS® from BioDelivery Sciences

GlobeNewswire May 11, 2016

BioDelivery Sciences Provides Corporate Update and Reports First Quarter 2016 Financial Results

PR Newswire May 10, 2016

BioDelivery Sciences to Host Conference Call and Webcast of First Quarter 2016 Results on Tuesday, May 10

PR Newswire May 3, 2016

BioDelivery Sciences Announces Acceptance of an Abstract to the International Conference on Opioids on the Impact of a State Formulary Conversion to BUNAVAIL

PR Newswire April 29, 2016

U.S. Patent and Trademark Office Upholds the Validity of MonoSol Rx's US Patent No. 8,765,167 in the Face of Multiple Inter Partes Review Challenges Brought by BioDelivery Sciences International, Inc. (BDSI)

GlobeNewswire April 7, 2016

BioDelivery Sciences to Present Today at the 28th Annual ROTH Conference

PR Newswire March 14, 2016

BioDelivery Sciences Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results

PR Newswire March 10, 2016

BioDelivery Sciences to Present at the Cowen and Company 36th Annual Healthcare Conference and the 28th Annual ROTH Conference

PR Newswire March 4, 2016

BioDelivery Sciences to Host Conference Call and Webcast of Fourth Quarter and Full-Year 2015 Results on Thursday, March 10

PR Newswire March 3, 2016